Joseph Letourneau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Joseph Letourneau has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Mitchell P. Rosen
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, USA, 94143
3 shared publications - Sai-Wing Chan
University of California, San Francisco, Department of Obstetrics, Gynecology and Reproductive Sciences, San Francisco, CA USA
2 shared publications - Wael H. Salem
University of Southern California, 020 Zonal Ave, IRD Room 533, Los Angeles, CA, 90033, USA.
2 shared publications - Aylin Pelin Cil
American Hospital, Istanbul, Turkey
1 shared publication Charles E McCulloch
1 shared publicationErin E Niemasik
1 shared publication
Latest Publications
- Open Access
- 2 March 2017
- Published by Springer Nature in Contraception and Reproductive Medicine
- Vol. 2 (1) , 1-7
Cancer survivors of gynecologic malignancies are at risk for decreased opportunity for fertility preservation
Cancer survivors rate fertility as one of the most important determinants of their quality of life in the years after cancer treatment. We seek to describe the reproductive goals of women affected by gynecologic cancers and investigate their specific challenges during fertility preservation (FP) counseling. Univariate & multivariate logistic regression were used for quantitative analysis of objective FP counseling measures between women with gynecologic (GYN) and non-gynecologic (non-GYN) cancers from a cross sectional survey. Framework analysis was conducted on patient perception of physician-patient interactions. Of the 2537 women contacted, 1892 responded and 1686 reported treatment with potential to impact fertility. Among women with GYN cancers 52% wanted future children. Women <35 years were interested in FP (74%). Women with Gyn cancers received less FP counseling than women with non Gyn cancer (OR 0.5 95% CI 0.4–0.6). Three hundred twenty-four patients gave qualitative answers. Patient identified barriers included incomplete FP information (59%), nondisclosure (29%), a disinterest in FP (5%), and a perceived urgency to start treatment (7%). Women with gynecologic cancers are less likely to be counseled about FP in comparison to women not affected by gynecologic cancers despite having similar fertility goals. We have identified patient perceived barriers to optimal FP counseling which may be improved upon to increase the value of FP and optimize quality of life for cancer survivors of gynecologic malignancies.
- 2 March 2017
- Published by Springer Nature in Contraception and Reproductive Medicine
- Vol. 2 (1) , 1-7
Open AccessCancer survivors of gynecologic malignancies are at risk for decreased opportunity for fertility preservation
Cancer survivors rate fertility as one of the most important determinants of their quality of life in the years after cancer treatment. We seek to describe the reproductive goals of women affected by gynecologic cancers and investigate their specific challenges during fertility preservation (FP) counseling. Univariate & multivariate logistic regression were used for quantitative analysis of objective FP counseling measures between women with gynecologic (GYN) and non-gynecologic (non-GYN) cancers from a cross sectional survey. Framework analysis was conducted on patient perception of physician-patient interactions. Of the 2537 women contacted, 1892 responded and 1686 reported treatment with potential to impact fertility. Among women with GYN cancers 52% wanted future children. Women <35 years were interested in FP (74%). Women with Gyn cancers received less FP counseling than women with non Gyn cancer (OR 0.5 95% CI 0.4–0.6). Three hundred twenty-four patients gave qualitative answers. Patient identified barriers included incomplete FP information (59%), nondisclosure (29%), a disinterest in FP (5%), and a perceived urgency to start treatment (7%). Women with gynecologic cancers are less likely to be counseled about FP in comparison to women not affected by gynecologic cancers despite having similar fertility goals. We have identified patient perceived barriers to optimal FP counseling which may be improved upon to increase the value of FP and optimize quality of life for cancer survivors of gynecologic malignancies.
- 1 March 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (3) , e26
Higher antral follicle count associated with earlier return of ovarian function in breast cancer patients with temporary amenorrhea after chemotherapy
- 1 March 2017
- Published by Elsevier in Fertility and Sterility
- Vol. 107 (3) , e26
Higher antral follicle count associated with earlier return of ovarian function in breast cancer patients with temporary amenorrhea after chemotherapy
- 1 October 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 139 (1) , 141-147
Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery
- 1 October 2015
- Published by Elsevier in Gynecologic Oncology
- Vol. 139 (1) , 141-147
Sexual satisfaction and quality of life in survivors of localized cervical and ovarian cancers following fertility-sparing surgery
- 7 October 2013
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 31 (06) , 462-468
Accelerating Ovarian Age: Cancer Treatment in the Premenopausal Woman
The reproductive sequelae of cancer treatments may provide an important model of accelerated ovarian aging. Tens of thousands of women treated for cancer each year experience infertility and early menopause as a result of treatment. A spectrum of reproductive compromise commonly ranges from immediate menopause at the time of cancer treatment to the less proximate outcome of early menopause in the years to decades after treatment. A woman's reproductive lifespan can be shortened after chemotherapy or radiation because such treatments likely decrease the number of viable eggs after treatment. This acceleration in the decline of the number of follicles leads to increased rates of not only infertility and miscarriage but also early menopause, which represents the most extreme form of accelerated ovarian aging. The degree of reproductive impairment is dependent on chronologic age and the diagnosis or treatment. The variation in outcomes that persist may be partially explained by pretreatment ovarian reserve. Establishing the use of clinical predictors such as ovarian reserve markers to effectively anticipate such outcomes is an obvious and important keystone in the foundation of cancer survivorship research. An improved understanding of cancer treatment's ability to accelerate follicle death, decrease fecundability, and initiate an earlier menopause could provide a clinically relevant, time-shortened, and reproducible snapshot into the basic biology of ovarian aging.
- 7 October 2013
- Published by Georg Thieme Verlag KG in Seminars in Reproductive Medicine
- Vol. 31 (06) , 462-468
Accelerating Ovarian Age: Cancer Treatment in the Premenopausal Woman
The reproductive sequelae of cancer treatments may provide an important model of accelerated ovarian aging. Tens of thousands of women treated for cancer each year experience infertility and early menopause as a result of treatment. A spectrum of reproductive compromise commonly ranges from immediate menopause at the time of cancer treatment to the less proximate outcome of early menopause in the years to decades after treatment. A woman's reproductive lifespan can be shortened after chemotherapy or radiation because such treatments likely decrease the number of viable eggs after treatment. This acceleration in the decline of the number of follicles leads to increased rates of not only infertility and miscarriage but also early menopause, which represents the most extreme form of accelerated ovarian aging. The degree of reproductive impairment is dependent on chronologic age and the diagnosis or treatment. The variation in outcomes that persist may be partially explained by pretreatment ovarian reserve. Establishing the use of clinical predictors such as ovarian reserve markers to effectively anticipate such outcomes is an obvious and important keystone in the foundation of cancer survivorship research. An improved understanding of cancer treatment's ability to accelerate follicle death, decrease fecundability, and initiate an earlier menopause could provide a clinically relevant, time-shortened, and reproducible snapshot into the basic biology of ovarian aging.
- Open Access
- 1 January 2013
- Published by Herbert Publications PVT LTD in journal of Cancer Therapeutics and Research
- Vol. 2 (1) , 16
Temporary amenorrhea predicts future infertility in young women treated with chemotherapy
Background: Little is known about how to predict post-treatment reproductive health outcomes in reproductive-age women with cancer. We sought to determine whether predictors like age, parity, temporary
- 1 January 2013
- Published by Herbert Publications PVT LTD in journal of Cancer Therapeutics and Research
- Vol. 2 (1) , 16
Open AccessTemporary amenorrhea predicts future infertility in young women treated with chemotherapy
Background: Little is known about how to predict post-treatment reproductive health outcomes in reproductive-age women with cancer. We sought to determine whether predictors like age, parity, temporary